The U.S. Supreme Court has decided to hear a case between Amarin Pharma and generic drugmaker Hikma that puts so-called ...
Supreme Court to decide if “generic version” marketing can support induced infringement claims. On Jan. 16, 2026, ...
A US Supreme Court fight over how branded drugs’ makers must plead induced infringement in “skinny-label” patent suits could ...
On January 16, 2026, the U.S. Supreme Court agreed to hear Hikma Pharmaceuticals USA, Inc. v. Amarin Pharma, Inc., a patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results